Atara Biotherapeutics (ATRA) Gross Profit (2022 - 2026)

Atara Biotherapeutics has reported Gross Profit for 5 years, with the latest figure at $392000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 99.5% year-over-year to $392000.0; the trailing twelve-month figure through Mar 2026 stood at $22.2 million (down 86.12% YoY), and the FY2025 full-year result was $99.6 million, down 7.76% from the prior year.
• Gross Profit for Q1 2026 stood at $392000.0, down from $1.5 million in the prior quarter.
• The five-year high for Gross Profit was $77.7 million in Q1 2025, with the low at -$2.1 million in Q2 2023.
• Historically, Gross Profit has averaged $16.7 million across 5 years, with a median of $5.3 million in 2022.
• Annual changes were most pronounced in 2023 — Gross Profit plunged 104.08% — and 2024, when it jumped 6931.87%.
• Atara Biotherapeutics' Gross Profit stood at $221000.0 in 2022, then soared by 676.47% to $1.7 million in 2023, then soared by 1412.7% to $26.0 million in 2024, then slumped by 94.26% to $1.5 million in 2025, then tumbled by 73.71% to $392000.0 in 2026.
• The last three Gross Profit figures came in at $392000.0 (Q1 2026), $1.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.